Advancing cancer therapy with custom-built alternating electric field devices
Abstract Background In glioblastoma (GBM) therapy research, tumour treating fields by the company Novocure™, have shown promise for increasing patient overall survival. When used with the chemotherapeutic agent temozolomide, they extend median survival by five months. However, there is a space to de...
Saved in:
| Main Authors: | Isobel Jobson, Nguyen T. N. Vo, Edward Kujawinski, Chris Denning, Snow Stolnik, Veeren M. Chauhan, Frankie Rawson |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-01-01
|
| Series: | Bioelectronic Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s42234-024-00164-3 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Invasive and non-invasive tumor-treating electric field (TTF) therapy: An exciting advance in oncologic neuromodulation
by: Thomas Eckert, et al.
Published: (2025-09-01) -
Tumor treating fields: a new treatment for glioblastoma
by: Dimitar Slavkov, et al.
Published: (2023-03-01) -
Optune in Glioblastoma: Revolutionizing Treatment with Tumor Treating Fields
by: Patrycja Długozima, et al.
Published: (2025-05-01) -
Limited survival benefit in patients diagnosed with glioblastoma post-2016: a SEER population based registry analysis
by: Shaurya Dhingra, et al.
Published: (2025-06-01) -
Comprehensive simulations of intracellular electric fields during exposure to tumor treating fields
by: Kaida Liu, et al.
Published: (2025-05-01)